Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "data"

1681 News Found

New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D
Digitisation | May 27, 2021

New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D

The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.


States need to capture vaccination data: R. S. Sharma
Policy | January 11, 2021

States need to capture vaccination data: R. S. Sharma

Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.


Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Digitisation | September 11, 2025

Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines


Congruence gets $32 million financing to advance genetic obesity candidate drug
News | September 09, 2025

Congruence gets $32 million financing to advance genetic obesity candidate drug

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity


MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline
News | September 09, 2025

MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval


FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease
Drug Approval | September 08, 2025

FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease

Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD


FDA completes inspection at Biocon Biologics' facility in Bengaluru
News | September 05, 2025

FDA completes inspection at Biocon Biologics' facility in Bengaluru

The U.S. FDA issued a Form 483 with five observations


AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
Diagnostic Center | September 05, 2025

AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue


Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study
Diagnostic Center | September 04, 2025

Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study

Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol